clinical trial · NCT04956289
Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys With DMD (Galactic53)
NS Pharma, Inc.·phase2·completed·n = 20
Duchenne Muscular DystrophyViltolarsen
brief summary
This is a phase II, open-label study where weekly doses of 80 mg/kg viltolarsen is administered intravenously over a 48-week treatment period to ambulant and non-ambulant DMD patients over the age of 8 years.
started
Jul 1, 2021
primary completion
Jun 20, 2023
completion
Jul 13, 2023
last updated
Aug 20, 2024
official title
A Phase 2 Open-label Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys With Duchenne Muscular Dystrophy (DMD) Compared to Natural History Controls
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol